此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

大分割质子治疗 II-III 期非小细胞肺癌的 I/II 期研究

2026年9月25日 更新者:Proton Collaborative Group

The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using standard chemotherapy in combination with hypofractionated proton radiation therapy. Hypofractionation is a technique that delivers higher daily doses of radiation over a shorter period of time.

研究概览

地位

主动,不招人

条件

详细说明

Conventional fractionated photon-based radiotherapy to 60-63 Gy at 1.8-2 Gy/fraction with concurrent chemotherapy remains the standard treatment practice in patients with stage III non-small cell lung carcinoma (NSCLC) with local control rates of approximately 50% and a median overall survival of just 18 months.Unfortunately, even the standard treatment has significant toxicity with approximately 40% of patients developing grade 3 or higher acute toxicities in the RTOG 9410 study.1 These outcomes are poor and more effective treatment regimens are needed.

Higher doses of radiation have been hypothesized to improve local control in patients with stage III NSCLC. This is expected to translate into better overall survival.Given the significant improvements in outcome in patients receiving hypofractionation for stage I NSCLC, perhaps similar gains could be achieved if hypofractionated radiotherapy could be safely delivered to stage II-III NSCLC with concurrent chemotherapy. Hypofractionated radiotherapy may offer improvement in local control compared with conventional fractionation that may translate into improved overall survival. Furthermore, hypofractionation will shorten the time interval during which patients are receiving less aggressive chemotherapy. Proton therapy is a highly conformal radiotherapy technique that takes advantage of the proton's characteristic Bragg Peak, resulting in significant reductions in the exit dose of the treatment beam. Thus, proton therapy can substantially reduce the dose to critical structures even compared with IMRT.

This study will investigate the safety and efficacy of delivering hypofractionated proton therapy with concurrent chemotherapy in patients with stage II-III NSCLC

研究类型

介入性

注册 (实际的)

32

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Florida
      • Jacksonville、Florida、美国、32206
        • University of Florida Proton Therapy Institute
    • Illinois
      • Warrenville、Illinois、美国、60555
        • Northwestern Medicine Chicago Proton Center
    • Maryland
      • Baltimore、Maryland、美国、21201
        • Maryland Proton Treatment Center
    • New Jersey
      • Somerset、New Jersey、美国、08873
        • Princeton ProCure Management LLC
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73142
        • Oklahoma Proton Center
    • Virginia
      • Hampton、Virginia、美国、23666
        • Hampton University Proton Therapy Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Pathologically confirmed invasive non-small cell lung cancer within 12 weeks prior to study registration. OR Pathologically confirmed invasive non-small cell lung cancer within 6 months prior to study registration if the patient received induction chemotherapy.

  • AJCC (American Joint Committee on Cancer) 7th Ed. clinical stage II-III.

  • ECOG Performance status 0-1 within 8 weeks prior to study registration.

  • Patient must give study-specific informed consent on an IRB-approved consent prior to any research-related procedures or study treatment.

  • Patient must be at least 18 years old at the time of consent.

  • Patient must complete all required tests in section 4.

  • Lab results per the following within 4 weeks prior to study registration:

    • Absolute neutrophil count (ANC) >1,800 cells/mm3.
    • Platelets > = 100,000 cells/mm3.
    • Hemoglobin > =10 g/dl. The use of transfusion or other intervention to achieve Hgb ≥10.0 g/dl is acceptable.
    • AST/SGOT and ALT/SGPT < 2.5 x the institutional upper limit of normal (IULN).
  • Post exploratory thoracotomy must be done > 3 weeks prior to study registration or patient did not have post exploratory thoracotomy.

  • PFT (pulmonary function test) with a FEV1 > 0.75 liters/second within 16 weeks prior to study registration.

  • Patients must be evaluated by a thoracic surgeon, pulmonologist or medical oncologist and deemed medically or surgically unacceptable for resection.

Exclusion Criteria:

  • Evidence of distant metastasis (M1) involvement.
  • Prior radiotherapy to thoracic area.
  • Unintentional weight loss >10% within 4 weeks prior to study registration.
  • Pregnant and/or breast-feeding women, or patients (men and women) of child-producing potential not willing to use medically acceptable forms of contraception while on study treatment and for at least 12 months after study treatment. Pregnancy testing is not necessary for women who have had a hysterectomy or have not had a menstrual period for at least 24 consecutive months.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:质子放疗与化疗

RADIATION: Proton Radiotherapy

Dose Level 1: 60 Gy (RBE) at 2.5 Gy(RBE) per fraction x 24 fractions

Dose Level 2: 60 Gy (RBE) at 3 Gy (RBE) per fraction x 20 fractions

Dose Level 3: 60.01 Gy (RBE) at 3.53 Gy (RBE) per fraction x 17 fractions

Dose Level 4: 60 Gy (RBE) at 4 Gy (RBE) per fraction x 15 fractions

CONCURRENT CHEMOTHERAPY:

Paclitaxel at a dose of 45 mg/m2 and Carboplatin at a dose of AUC 2 mg/min/ml (a total of 3-5 weekly doses) OR Cisplatin 50mg/m2 days 1, 8, 29, and 36 and Etoposide 50mg/m2 days 1-5, 29-33. For non squamous histology, Carboplatin AUC 5 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days OR Cisplatin 75 mg/m2 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days.

Adjuvant chemotherapy is optional.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
第二阶段:确定存活至少 12 个月的患者百分比
大体时间:12个月
12个月
Phase I: Establish the maximum tolerated dose of radiotherapy in terms of Gy (RBE)/fraction using hypofractionated proton therapy concurrently with chemotherapy.
大体时间:Weekly until completion of radiation treatment

This phase will have a minimum of 2 treated patients and we anticipate that the MTD will be located before a maximum of 28 patients are treated. The trial begins by treating 5 patients at 2.5 Gy (RBE)/fraction to a dose of 60 Gy (RBE).

Weekly until completion of radiation treatment

次要结果测量

结果测量
大体时间
评估同步化疗与大分割质子治疗的急性和晚期不良事件。
大体时间:平均每 3 个月一次,持续 5 年
平均每 3 个月一次,持续 5 年
分析疾病控制和总生存期。
大体时间:在 2 岁和 5 岁时
在 2 岁和 5 岁时

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Brad Hoppe, MD、Proton Collaborative Group

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2013年3月1日

初级完成 (估计的)

2038年1月1日

研究注册日期

首次提交

2013年1月11日

首先提交符合 QC 标准的

2013年1月15日

首次发布 (估计的)

2013年1月17日

研究记录更新

最后更新发布 (实际的)

2026年9月29日

上次提交的符合 QC 标准的更新

2026年9月25日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅